Items Tagged ‘florida news release’
Posted on April 16th, 2014 by Kevin Punsky
The $39.5-million grant to fund stroke study is one of largest ever awarded to investigators at Mayo Clinic in Florida
JACKSONVILLE, Fla. — Is medicine as safe and effective as surgery or stenting in preventing a stroke caused by the buildup of plaque in the carotid artery? Thomas G. Brott, M.D., a neurologist at Mayo Clinic in Florida, aims to find out.
“It’s a critical question. The quality medicines we have today may mean that it is not necessary to perform invasive procedures on patients who do not have warning signs of stroke,” Dr. Brott says. “More than 100,000 carotid surgeries and carotid artery stentings are performed each year in the United States on such patients at risk — and that may not be necessary.”
To find the answer, the National Institute of Neurological Disorders and Stroke (NINDS) has awarded Dr. Brott and his colleague, James Meschia, M.D., $39.5 million — one of the largest grants ever awarded to Mayo Clinic in Florida investigators. The grant funds a seven-year clinical trial that will enroll 2,480 patients in 120 centers in the United States, Canada, Europe and Australia. The study, known as CREST-2, is expected to begin enrolling patients this summer. Management of the patient data and the statistical analysis will be carried out at the University of Alabama at Birmingham under the direction of George Howard, Dr.PH.
Read the rest of this entry »
Posted on March 7th, 2014 by Shawn Bishop
test test test
The painful rheumatic condition gout is often associated with the big toe, but Mayo Clinic has found that patients at highest risk oayo researchers were presenting in Madrid at the European League Against nual meeting.
Posted on February 10th, 2014 by Kevin Punsky
JACKSONVILLE, Fla. — Patients with a common form of lung cancer — lung squamous cell carcinoma — have very few treatment options. That situation may soon change.
A team of cancer biologists at Mayo Clinic in Florida is reporting in the Feb. 10 issue of Cancer Cell the discovery of two oncogenes that work together to sustain a population of cells in lung squamous cell carcinoma, which may be responsible for the lethality of the disease. When these cells, termed cancer stem cells, are inhibited, tumors cannot develop.
Journalists: Sound bites with Dr. Fields are available in the downloads.
“Cancer stem cells are a small population of cells in a tumor that can self-renew and grow indefinitely. They resist most treatments and are thought to be responsible for relapse,” says the study’s senior author, Alan P. Fields, Ph.D., the Monica Flynn Jacoby Professor of Cancer Studies at Mayo Clinic in Florida. “If you can shut down cancer stem cells, you may be able to stop relapse after therapy,” he says.
Read the rest of this entry »
Posted on February 6th, 2014 by Kevin Punsky
MARIETTA, Ga. — Feb. 6 — WellStar Health System (WellStar) and Mayo Clinic today announced that the metro Atlanta-based health system is joining the Mayo Clinic Care Network, a national network of like-minded organizations that share a commitment to better serving patients and their families. WellStar is the largest member of the Mayo Clinic Care Network in the southeast and the only member in metro Atlanta.
Using digital technology to promote physician collaboration and sharing of the latest medical information, experts from WellStar and Mayo Clinic will work together to further enhance the delivery of healthcare for patients, allowing many patients to avoid unnecessary travel for answers to complex medical questions.
“WellStar is home to some of the most accomplished and preeminent physicians in the Southeast,” says Robert Jansen, M.D., executive vice president and chief administrative medical officer of WellStar. “Working with Mayo Clinic through the Mayo Clinic Care Network offers our physicians a new resource to ensure the kind of innovative and leading care that patients have grown to expect from WellStar.” Read the rest of this entry »
Posted on February 3rd, 2014 by Paul Scotti
JACKSONVILLE, Fla. — Feb. 3 — Uggie, the scene-stealing Jack Russell terrier in the 2012 Oscar-winning film “The Artist” will visit Mayo Clinic on Thursday, Feb. 6. Uggie will be in Jacksonville to meet Mayo’s Caring Canines, the volunteer dogs who greet patients and visitors at the clinic.
The visit by Uggie and his owner/trainer, Omar Von Muller, is open to the public, at 12:30 p.m. Thursday in Walker Auditorium in the clinic’s Davis Building. Von Muller will share Uggie’s amazing success story of going from a puppy headed for the pound to worldwide fame. Uggie will perform some of the tricks that delighted fans of “The Artist” in which he portrayed a loyal dog who courageously rescues his owner from a fire. The film received five Oscars, including Best Picture, Best Director and Best Actor, Jean Dujardin.
There are 19 volunteer dogs in Mayo’s Caring Canines program. They make daily “meet-and-greet” visits to patients and visitors, providing warmth and unconditional love.
“The Caring Canines play a valuable role in supporting Mayo Clinic’s commitment to the healing of mind, body and spirit,” says Peter Dorsher, M.D., chair of Mayo’s Department of Physical Medicine and Rehabilitation. “Uggie’s impact on people worldwide is further evidence of the human/animal bond and how it can improve our health and well-being. We’re delighted to have him meet our volunteer dogs.” Read the rest of this entry »
Posted on December 4th, 2013 by Shawn Bishop
JACKSONVILLE, Fla. — Like a car with a front and back end, a steering mechanism and an engine to push it forward, cancer cells propel themselves through normal tissues and organs to spread cancer throughout the body. Researchers at Mayo Clinic in Florida, however, have managed to turn these cells into shapes like a round fried egg and an exaggerated starfish that sticks out in many directions — both of which cannot now move.
In research published in the December issue of Molecular and Cellular Biology, investigators reveal how interplay of molecules keeps cancer cells moving forward, and how disturbing the balance of these proteins pushes their shape to change, stopping them in their tracks.
Investigators say they have already identified a number of agents — some already used in the clinic for different disorders — that may force shape-shifting in tumor cells.
"We are starting to understand mechanistically how cancer cells move and migrate, which gives us opportunities to manipulate these cells, alter their shape, and stop their spread," says the study's lead investigator, Panos Z. Anastasiadis, Ph.D., chair of the Department of Cancer Biology at Mayo Clinic in Florida.
"It is the spread — the metastasis — of cancer that is largely responsible for the death of cancer patients, so stopping these cells from migrating could potentially provide a treatment that saves lives," he says.
The study was conducted using tumor material from breast and brain (glioblastoma) cancer. Both of these tumors are generally lethal when they spread — breast to other organs, and brain cancer as it crawls throughout the brain.
The researchers found that a protein called Syx is key to determining how tumor cells migrate. When researchers removed Syx from the cancer cells, they lost their polarity — their leading and trailing edges — and morphed into the fried egg shape. "They are now unable to sense direction, so they are not going anywhere," Dr. Anastasiadis says.
Posted on November 18th, 2013 by Kevin Punsky
JACKSONVILLE, Fla. — Thomas G. Brott, M.D., a neurologist and director for research at Mayo Clinic in Florida, has been named the recipient of the American Heart Association's 2013 Clinical Research Prize.
The award recognizes and rewards an individual who is making outstanding contributions to the advancement of cardiovascular science and who currently heads an outstanding cardiovascular clinical research laboratory, according to the American Heart Association (AHA). Dr. Brott will be honored on stage during the opening ceremony of the American Heart Association's 2013 annual meeting in Dallas.
He is the first Mayo Clinic investigator to receive the prestigious prize, which has been awarded annually by the American Heart Association since 2005.
"This award is well deserved. Dr. Brott is a pioneer in the field of stroke and cerebrovascular disease research, and his mission to find the best therapies possible for patients has certainly saved lives," says William C. Rupp, M.D., chief executive officer at Mayo Clinic in Florida.
Dr. Brott was a leading investigator in the studies that identified tissue plasminogen activator (t-PA) as an effective acute treatment for ischemic stroke. He and his team treated the very first patients using this therapy. Along with his colleagues, Dr. Brott defined the evolution of spontaneous intracerebral hemorrhage during the first hours after onset. In 1998, Dr. Brott came to Mayo Clinic's campus in Florida where he and his colleagues initiated the first NIH-funded genome-wide screen for stroke susceptibility.
Dr. Brott has led federally funded national clinical trials that aim to discover best treatment for stroke and uncover risk factors for the disorder. For example, he is principal investigator for the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), a study that compares two different treatments for their ability to reduce risk for stroke. The study was supported by the National Institute of Neurological Disorders and Stroke.
He also played a key role in designing the National Institutes of Health Stroke Scale (NIHSS), a tool used internationally that measures stroke-related neurologic deficits.
Posted on November 14th, 2013 by Paul Scotti
JACKSONVILLE, Fla. — The Blood and Marrow Transplantation Program of Mayo Clinic, Nemours Children's Clinic, Jacksonville, and Wolfson Children's Hospital has been awarded a three-year accreditation renewal by the Foundation for the Accreditation of Cellular Therapy (FACT). The foundation awarded the accreditation renewal after thorough site visits at all collection, transplantation and laboratory facilities at the three locations.
"We are pleased that Mayo Clinic, Nemours Children's Clinic and Wolfson Children's Hospital have met the requirements of the Foundation and have been granted accreditation for their joint Blood and Marrow Transplantation Program," said Phyllis Warkentin, M.D., FACT medical director.
"The teamwork and cooperation between all three organizations in the program has never been better," said Blood and Marrow Transplant Program Director Michael Joyce, M.D., Ph.D., a pediatric hematologist/oncologist at Nemours Children's Clinic, Jacksonville. "FACT accreditation is a promise to our patients that we are adhering to and meeting the highest standards in the field. The hematology/oncology physicians, nurses, laboratory and support staff of Nemours, Wolfson Children's and Mayo Clinic work very hard to achieve maintain these standards."
The joint program was created in 2001 to allow for greater collaboration in physician and staff expertise, research and clinical protocols. Wolfson Children's Hospital and Nemours Children's Clinic, Jacksonville, will celebrate their Blood and Marrow Transplant Program's 20th anniversary next year. Many patient referrals to the Blood and Marrow Transplant Program come from physicians in Jacksonville, across Florida and south Georgia, across the United States and internationally. Since it was established, the combined program has transplanted patients with a variety of illnesses including leukemia, neuroblastoma, sickle cell disease, bone marrow disorders, multiple myeloma, lymphoma, brain tumors, Ewing's sarcoma, and amyloidosis. Stem cell sources include the patient, immediate family members, volunteer unrelated adult marrow donors or donated umbilical cord blood donor units. More than 970 transplants have been completed during this time.
The program shares a single cryopreservation laboratory (where hematopoietic stem cells are frozen and processed) at Mayo Clinic. Mayo maintains the program's adult Blood and Marrow Transplant Unit, and Wolfson Children's Hospital maintains Pediatric Blood and Marrow Transplant beds on the Hematology/Oncology Unit in the J. Wayne and Delores Barr Weaver Tower. The joint program shares information systems, quality and other clinical and administrative staff.
"We are excited to receive this accreditation. It is a welcome recognition and 'badge of honor' for our program. It also informs and assures our patients, referring physicians and insurance companies of the highest standards of patient care and laboratory practices in our program," said Vivek Roy, M.D., hematologist/oncologist at Mayo Clinic in Florida and medical director of the adult Blood and Marrow Transplant Program.
Posted on November 13th, 2013 by Kevin Punsky
COLUMBUS, GA. — Building on its reputation for delivering high quality and compassionate care to the communities in which it serves, St. Francis in Columbus, Ga., becomes the most recent member of the Mayo Clinic Care Network, representatives from Mayo Clinic and St. Francis announced today. The Mayo Clinic Care Network shares Mayo Clinic's knowledge and expertise with health care systems interested in working together to enhance the quality and delivery of health care for their patients. St. Francis is the first organization in Georgia to join the Mayo Clinic Care Network.
"St. Francis is proud to be a Mayo Clinic Care Network member," said Robert Granger, president and CEO of St. Francis. "As part of the Mayo Clinic Care Network, our physicians will be able to reach out to Mayo Clinic specialists as they consider the care needs for their patients. This collaboration is a continuation of St. Francis' commitment of doing what is best for health care in our community and will enhance patient care for the citizens of Columbus and the Chattahoochee Valley."
St. Francis underwent a thorough evaluation process based on quality, service and operational criteria. The assessment confirmed the commitment St. Francis shares with Mayo Clinic in improving the delivery of health care. St. Francis' membership is a direct result of its culture and dedication to providing compassionate patient care.
"We are pleased to welcome St. Francis, an award-winning regional hospital that is continuously recognized for providing outstanding patient care, as a member of the Mayo Clinic Care Network," saysStephen Lange, M.D., Southeast medical director of the Mayo Clinic Care Network. "We look forward to working closely with St. Francis to help them continue to provide the highest quality of care and best possible outcomes for their patients."
St. Francis physicians will be able to connect with Mayo Clinic specialists on questions of complex medical care using an electronic consulting technique called eConsults. They also will have 24/7 access to Mayo-vetted medical information and guidelines through AskMayoExpert, a Web-based resource created for physicians and other health care providers. These tools, in addition to health care consulting related to clinical and business processes, will allow staff at St. Francis to accelerate innovations in care in support of the organization's mission to continuously improve the quality of health in the community.
St. Francis employs more than 2,300 associates with more than 300 community physicians (100 employed) through the St. Francis Medical Group. The hospital opened in 1950 and is currently licensed for 376 beds.
The Mayo Clinic Care Network represents non-ownership relationships. Unlike the integration of Georgia's Satilla Regional Medical Center, which became the Mayo Clinic Health System in Waycross, St. Francis will continue to be independently owned and operated.
The primary goal of the Mayo Clinic Care Network is to help people gain the benefits of Mayo Clinic expertise close to home, ensuring that patients need to travel for care only when necessary.
The network, launched in 2011, has 22 member organizations based in Arizona, Florida, Georgia, Illinois, Kentucky, Michigan, Minnesota, Missouri, Montana, New Hampshire, North Dakota and Wisconsin as well as Puerto Rico and Mexico.
St. Francis, a 376-bed facility, offers a full range of inpatient, outpatient and emergency room services and is the only area hospital offering open heart surgery. With more than 2,000 employees, 300 physicians and the latest technology, we strive to help you regain and maintain your health. Our overriding goal is to provide you with the best possible care. For more information, visithttp://www.wecareforlife.com.
Journalists can become a member of the Mayo Clinic News Network for the latest health, science and research news and access to video, audio, text and graphic elements that can be downloaded or embedded.
Posted on November 12th, 2013 by Kevin Punsky
JACKSONVILLE, Fla. — Researchers at Mayo Clinic in Florida, the University of Florida in Gainesville, and the Institute for Systems Biology in Seattle have received a $7.5 million grant from the National Institutes of Health to take a new and more expanded approach to identifying drug targets to treat and possibly prevent Alzheimer's disease.
VIDEO ALERT: Video resources including an interview with Dr. Ertekin-Taner describing the study can be found on the Mayo Clinic News Network.
The investigators are working together to understand the role that innate immunity — the body's defense system — plays in Alzheimer's disease, a disorder of dementia that is rapidly increasing as the population ages.
The teams are focused on uncovering and manipulating the key molecular players in innate immunity with an ultimate goal of developing novel therapies for Alzheimer's disease, says neurologist and neuroscientist Nilufer Ertekin-Taner, M.D., Ph.D., one of the grant's two principal investigators from Mayo Clinic in Florida. The other is Steven Younkin, M.D., Ph.D.
"When activated, human innate immunity results in inflammation, and previous research on this response to development of Alzheimer's disease has been contradictory because no one has yet looked at the whole picture of this effect over time," says Dr. Ertekin-Taner. "It may be that an initial inflammatory response is beneficial, perhaps even protective, but a lengthy response to toxic proteins acts to kill healthy neurons.
"Our goal is to understand exactly if and when an innate immune response is good, and when it is bad, and to identify drug targets that enhance this protective effect and shut down the destructive side of this inflammation."